|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
CORTICOSTEROIDS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CORTICOSTEROIDS, TEND TO PRODUCE HYPERGLYCEMIA AND MAY LEAD TO LOSS OF GLYCEMIC CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
CORTICOSTEROIDS MAY INCREASE EXCRETION OF THE DRUG
|
APROTININ IS INCOMPATIBLE WITH THE DRUG
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CORTICOSTEROIDS MAY INTERFERE WITH THE DEVELOPMENT OF IMMUNE REACTION
|
CO-ADMINISTRATION WITH BUPROPION MAY ALTER THE SEIZURE THRESHOLD
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
OESTROGENS INCREASE LEVEL OF CORTICOSTEROID-BINDING GLOBULIN THERE BY INCREASING BOUND FRACTION, BUT ITS METABOLISM IS ALSO DECREASED,SO STEROID DOSE SHOULD BE REDUCED BUT INCREASED DOSE MAY BE REQUIRED WHEN OESTROGEN IS TERMINATED
|
CO-ADMINISTRATION MAY RESULT IN AN INCREASED OF G.I. ULCERATION OR OTHER COMPLICATIONS ; LOW DOSE OF ASPIRIN CAN BE USED WITH CELECOXIB
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|
CONCURRENT ADMINISTRATION MAY LEAD TO INCREASED G.I. SIDE EFFECTS
|